Mar 16, 2024, 20:07
Erman Akkus: HER2 and mCRC on Journal of Clinical Oncology
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“HER2 and mCRC on Journal of Clinical Oncology:
- HER2 gene expression is predictive and prognostic
- High expression -> better survivals
- Low expression -> favors bevacizumab (vs cetuximab)
HER2 amplification is not predictive or prognostic.
- 925 patients, samples from CALGB)/SWOG 80405 trial
- first line
- High HER2 expression: longer PFS (11.6 v 10 months, P = .012) and OS (32 v 25.3 months, P = .033), independent of treatment
- Low expression group, cetuximab ->. worse PFS (HR, 1.38 [1.12 to 1.71]; P = .0027) and OS (HR, 1.28 1.02 to 1.59]; P = .03) compared with bevacizumab.”
Visit the article website.
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12